Back to the real topics:
Earlier this month, stockbrokers Morgan’s summed up the state of play, “We view the
medical cannabis industry as a crowded trade and difficult space to navigate in the current
regulatory environment. Low levels of differentiation, slow moving regulation, weak clinical
evidence of efficacy, and expensive treatment costs compared to [Pharmaceutical
Benefits Scheme]-covered medicine makes it a slower moving proposition compared to
traditional drug assets.”
Market response also slowed with the decline in perceived value of licences following a
rash of issuance: at October 31, 2019 the Federal Office of Drug Control had issued 18
medical cannabis licences, eight cannabis research licences, 21 manufacture licences,
and 22 importation licences.
- Forums
- ASX - By Stock
- AC8
- AusCann up more than 65pc after completing testing of hard-shell capsules
AusCann up more than 65pc after completing testing of hard-shell capsules, page-84
-
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AC8 (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
AC8 (ASX) Chart |
Day chart unavailable